Amy Mahan Amy Mahan

Subscribe to Amy Mahan's Posts
Amy Mahan focuses her practice on intellectual property matters in the life sciences, pharmaceutical and biotechnology sectors. She works on a variety of patent infringement litigation cases involving monoclonal antibody biologics, cell-based immunotherapies and small molecule drugs. Read Amy Mahan's full bio.

Set Phase to Subject Matter Ineligible: More Accurate Haplotype Phase Method Still Abstract


By on Apr 1, 2021
Posted In Patents

In an appeal from a final rejection of a pending application, the US Court of Appeals for the Federal Circuit held that claims directed to methods for determining “haplotype phase” were correctly rejected as subject matter ineligible. In Re: Board of Trustees of The Leland Stanford Junior University, Case No. 20-1288 (Fed. Cir. Mar. 11,...

Continue Reading



Method for Determining Haplotype Phase Found Subject Matter Ineligible


By on Mar 17, 2021
Posted In Patents

In an appeal from a final rejection of a pending application, the US Court of Appeals for the Federal Circuit held that claims directed to methods for determining “haplotype phase” were correctly rejected under 35 USC § 101 as subject matter ineligible. In Re Board of Trustees of The Leland Stanford Junior University, Case No....

Continue Reading



Doesn’t Scan: Skin Cancer Detection Device Just Combination of Familiar Elements


By on Feb 25, 2021
Posted In Patents

The US Court of Appeals for the Federal Circuit overturned a finding of non-obviousness of certain claims relating to a device for the detection of skin cancer, finding that the Patent Trial & Appeal Board erred in applying the law of obviousness. Canfield Scientific, Inc. v. Melanoscan, LLC, Case No. 19-1927 (Fed. Cir. Feb. 18,...

Continue Reading



BLOG EDITORS

STAY CONNECTED

TOPICS

ARCHIVES